DexCom Stock Forecast, Price & News

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom or view top-rated stocks.

Wall Street analysts have given DexCom a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DexCom wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for DexCom.

DexCom will be holding an earnings conference call on Thursday, April 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Thursday, February, 11th. The medical device company reported $0.91 EPS for the quarter, meeting the consensus estimate of $0.91. The medical device company had revenue of $568.90 million for the quarter, compared to analysts' expectations of $558.41 million. DexCom had a trailing twelve-month return on equity of 27.29% and a net margin of 12.69%.
View DexCom's earnings history.

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DXCM shares have increased by 62.6% and is now trading at $410.38.
View which stocks have been most impacted by COVID-19.

DexCom updated its FY 2021 After-Hours earnings guidance on Thursday, February, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.21-2.31 billion, compared to the consensus revenue estimate of $2.33 billion.

17 brokerages have issued 1-year price objectives for DexCom's shares. Their forecasts range from $350.00 to $500.00. On average, they expect DexCom's share price to reach $442.75 in the next year. This suggests a possible upside of 7.9% from the stock's current price.
View analysts' price targets for DexCom or view top-rated stocks among Wall Street analysts.

347 employees have rated DexCom CEO Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among DexCom's employees.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD), STERIS (STE) and Varian Medical Systems (VAR).
View all of DXCM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a variety of institutional and retail investors. Top institutional investors include Chicago Capital LLC (0.16%), New York State Teachers Retirement System (0.12%), Chevy Chase Trust Holdings Inc. (0.07%), Scout Investments Inc. (0.06%), Retirement Systems of Alabama (0.04%) and Royal London Asset Management Ltd. (0.04%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Bridgette P Heller, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, Chevy Chase Trust Holdings Inc., Sentry Investment Management LLC, Retirement Systems of Alabama, Crossmark Global Holdings Inc., OLD National Bancorp IN, State of Alaska Department of Revenue, and Juncture Wealth Strategies LLC. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Bridgette P Heller, Jacob Steven Leach, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom or view top insider-selling stocks.

DXCM stock was bought by a variety of institutional investors in the last quarter, including Gradient Investments LLC, Mckinley Capital Management LLC Delaware, Scout Investments Inc., Chicago Capital LLC, DnB Asset Management AS, Everence Capital Management Inc., MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, and Exchange Traded Concepts LLC.
View insider buying and selling activity for DexCom or or view top insider-buying stocks.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DXCM stock can currently be purchased for approximately $410.38.

DexCom has a market capitalization of $39.69 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis.

DexCom employs 5,500 workers across the globe.

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.

DexCom was founded in 1999.

The official website for DexCom is www.dexcom.com.

DexCom is headquartered at 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]